Zimbabwe has declined a major US health deal valued at 367 million US dollars (£272m) over five years due to the United States' request for sensitive biological samples.
This move came to light following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since explained that the US was seeking biological samples for scientific study and commercial gain while was not willing to share the benefits from any future medical innovations.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more dialogue to find a deal agreeable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision comes after a similar situation in Kenya, where a high court halted a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral deals to boost transparency and accountability.
As per statements, 16 African countries have so far signed these new agreements, constituting over $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any corresponding promise of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our nation would provide the raw materials for medical research without any certainty that the end products would be accessible to our population should a future disease outbreak emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the global health body and its push of bilateral deals were undermining systems already set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This system is intended to ensure that when a country contributes its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how subsequent co-operation could be arranged in a manner that respects the independence and dignity of each country."
Health Experts Response
Medical experts said it recognised the official position, but recommended that talks must proceed since much of the nation's HIV programmes depended on external financing.
"In cases where technical issues exist, including those involving information security or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it commented.
This impasse underscores the complex challenges between accepting much-needed international aid and protecting local interests in an ever more interconnected world.